Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen

Taking place March 23-25, 2026, this three-day scientific forum will convene the world’s foremost NAD experts in Copenhagen to advance evidence-based dialogue and accelerate clinical translation

LOS ANGELES–(BUSINESS WIRE)–$NAGE #ClinicalResearch—Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD⁺ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces it is the headlining sponsor of the inaugural NAD for Health: Opportunities & Challenges scientific meeting hosted by the University of Copenhagen, taking place March 23–25, 2026 at the Royal Danish Academy of Sciences and Letters in central Copenhagen. Space is limited and registration is required; see registration details at the end of this release.

“Advancing NAD science requires more than promising data—it requires rigorous dialogue across disciplines, clear translational standards, and alignment on what meaningful outcomes look like,” said Andrew Shao, PhD, Senior Vice President of Regulatory and Scientific Affairs at Niagen Bioscience. “We are proud to support the University of Copenhagen’s inaugural NAD for Health conference because it creates an evidence-based forum that brings researchers and clinicians together to address the real barriers to translation—trial design, biomarkers, and regulatory considerations—so the field can move forward responsibly.”

This major international scientific meeting focuses on one of the most rapidly advancing areas in aging and metabolic research: NAD metabolism and its implications for human health. Bringing together thought leaders from world-renowned institutions, the conference is designed for an interdisciplinary audience spanning researchers, translational scientists, clinicians, and industry partners. The program will include thematic sessions, a panel discussion, and a dedicated poster session featuring short presentations from early-career researchers. The panel discussion will be livestreamed globally to broaden access to the latest advances in NAD biology and therapeutic potential. Details on the panel discussion livestream will be announced closer to the conference on the meeting website.

The meeting is being organized by Jonas Treebak, PhD, Associate Professor at the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen, and Vilhelm (Will) Bohr, MD, PhD, Affiliate Professor in Genome Instability and Neurodegeneration, also at the University of Copenhagen, in collaboration with an international organizing committee. Drs Bohr and Treebak previously conducted independent research on Niagen Bioscience’s patented nicotinamide riboside (NR) ingredient, Niagen, through the company’s external research program, and Dr. Bohr serves on the Scientific Advisory Board.

“This meeting was designed to convene the people generating the most important new insights in NAD biology—and to do it in a setting that encourages candid, evidence-based discussion,” said Dr. Treebak. “By bringing together basic, translational, and clinical perspectives, we can better identify the knowledge gaps that matter most and accelerate collaborative progress toward clinical translation.”

Key scientific themes include:

• NAD⁺ precursor strategies for rare orphan diseases, including Ataxia Telangiectasia (AT) 
• Targeted interventions to improve healthspan and delay age-related decline
• Circulation, tissues, and organ crosstalk in response to NAD⁺ precursor supplementation
• NAD-boosting strategies for neurodegenerative diseases
• Translational frameworks for clinical trials and dialogue between researchers and practitioners

“NAD⁺ is central to metabolism, mitochondrial functions, DNA repair, cellular resilience, and aging biology, and the field is advancing rapidly,” said Dr. Bohr. “This conference emphasizes both opportunities and limitations—so we can align on the standards, resources, and cross-sector collaboration needed to translate NAD research into meaningful health outcomes.”

Space is limited, and registration is required. Attendance is subject to confirmation and cannot be guaranteed. Individuals interested in attending should contact Cathleen Brahms, Events Manager at Niagen Bioscience, at [email protected] no later than Sunday, February 15, 2026.

For more information about the University of Copenhagen’s NAD for Health: Opportunities & Challenges Conference, please visit the conference website at https://eventsignup.ku.dk/nadforhealth. Learn more about Niagen Bioscience at www.niagenbioscience.com.

About Niagen Bioscience:

Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.

Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age.

At the heart of its clinically proven product portfolio is Niagen^® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen^®, the number one NAD+ boosting oral supplement in the United States^† (available at www.truniagen.com), and Niagen Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription.

Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, news, and financial information are regularly published.

^†Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 – 12/31/2024).

Forward Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes” “seeks,” “may,” “will,” “should,” “could,” “predicts,” “projects,” “continue,” “would” or the negative of such terms or other similar expressions.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those described. These risks and uncertainties include, but are not limited to, inflationary conditions and adverse economic conditions; our history of operating losses; the growth and profitability of our product sales; our ability to maintain and grow sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; risks of conducting business in China; including unanticipated developments in and risks related to the Company’s ability to secure adequate quantities of pharmaceutical-grade Niagen in a timely manner; the Company’s ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities required to compound and distribute pharmaceutical-grade Niagen to clinics; the Company’s ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list; the Company’s ability to maintain and enforce the Company’s existing intellectual property and obtain new patents; whether the potential benefits of NRC can be further supported; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities, including with respect to products seeking to compete in our market; economic and market instability, including as a result of tariffs or trade conflicts; and the risks and uncertainties associated with our business and financial condition in general, described in our filings with the Securities and Exchange Commission (SEC), including, without limitation, our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q as filed with the SEC.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

Contacts

Niagen Bioscience Media Contact:
Kendall Knysch, Senior Director of Media Relations & Partnerships
310.405.5227
[email protected]

Niagen Bioscience Investor Relations Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
[email protected]